A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 598-607

  Park, Man Young ^a   Yoon, Dukyong ^a   Lee, Kiyoung ^a   Kang, Seok Yun ^a   Park, Inwhee ^a   Lee, Suk Hyang ^b   Kim, Woojae ^a   Kam, Hye Jin ^a   Lee, Young Ho ^c   Kim, Ju Han ^d   Park, Rae Woong ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Adverse drug event; Electronic medical record; Pharmacovigilance; Postmarketing drug surveillance

Indexed keywords

ALGORITHM; ARTICLE; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TEACHING HOSPITAL;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ALGORITHMS; CHILD; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PRODUCT SURVEILLANCE, POSTMARKETING; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 79959556162     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2139     Document Type: Article

References (32)

1. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today 2009; 14: 343-357. DOI:10.1016/j.drudis.2008.12.012
2. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf 2007; 16: 359-365. DOI: 10.1002/pds.1323
3. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26: 159-186.
4. Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002; 25: 393-397.
5. Harmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008; 64: 743-752. DOI: 10.1007/s00228-008-0475-9
6. Hochberg AM, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria. Clin Pharmacol Ther 2009; 85: 600-606. DOI:10.1038/clpt.2009.26
7. Cerrito P. Application of data mining for examining polypharmacy and adverse effects in cardiology patients. Cardiovasc Toxicol 2001; 1: 177-179.
8. Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol 1989; 129: 837-849.
9. Choi NK, Chang Y, Choi YK, Hahn S, Park BJ. Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database. Pharmacoepidemiol Drug Saf 2010; 19: 238-246. DOI: 10.1002/pds.1902
10. Bate A. Bayesian confidence propagation neural network. Drug Saf 2007; 30: 623-625.
11. Strom BL, Kimmel SE. Textbook of pharmacoepidemiology. John Wiley & Sons: Chichester, West Sussex; Hoboken, NJ, 2006; 168-169.
12. Kelly WN. Potential risks and prevention, Part 1: fatal adverse drug events. Am J Health Syst Pharm 2001; 58: 1317-1324.
13. Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol 1999; 47: 557-564. DOI: 10.1046/j.1365-2125.1999.00926.x
14. Levy M, Azaz-Livshits T, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999; 54: 887-892.
15. Azaz-Livshits T, Levy M, Sadan B, Shalit M, Geisslinger G, Brune K. Computerized survelliance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309-314. DOI: 10.1046/j.1365-2125.1998.00685.x
16. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-2851.
17. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5: 305-314.
18. Bagheri H, Michel F, Lapeyre-Mestre M, et al. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 2000; 50: 479-484. DOI: 10.1046/j.1365-2125.2000.00282.x
19. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22: 161-168.
20. Honigman B, Lee J, Rothschild J, et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001; 8: 254-266.
21. Movig KL, Leufkens HG, Lenderink AW, et al. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 2002; 53: 363-369. DOI: 10.1046/j.1365-2125.2002.01550.x
22. Goettsch WG, Yin DD, Alemao E, Klungel OH, Stalenhoef AF, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004; 20: 1025-1033. DOI: 10.1185/030079904125004114
23. Raebel MA, Lyons EE, Chester EA, et al. Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. Arch Intern Med 2005; 165: 2395-2401.
24. Raebel MA, McClure DL, Simon SR, et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006; 40: 386-391.
25. ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007; 45: 13-19. DOI: 10.1515/CCLM.2007.009, 01/01/2007
26. Ramirez E, Carcas AJ, Borobia AM, et al. A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients. Clin Pharmacol Ther 2010; 87: 74-86. DOI:10.1038/clpt.2009.185
27. Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28: 1162-1164.
28. Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch 2004; 444: 87-89.
29. Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010; 33: 526-531. DOI: 10.2337/dc09-1506
30. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol. 2008; 66: 689-694.
31. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009; 18: 483-491.
32. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf 2011; 20: 292-299.